Antifibrotic effect of placental multipotent mesenchymal stromal cells in liver fibrosis

  • Dmitry Yurievich Grebnev Urals State Medical University, 3 Repin str., Ekaterinburg, 620028, Russian Federation; Institute of Medical Cell Technologies, 22a Karl Marx Str., Ekaterinburg, 620026, Russian Federation https://orcid.org/0000-0002-5698-8404
  • Irina Yurievna Maklakova Urals State Medical University, 3 Repin str., Ekaterinburg, 620028, Russian Federation; Institute of Medical Cell Technologies, 22a Karl Marx Str., Ekaterinburg, 620026, Russian Federation https://orcid.org/0000-0002-6895-7947
  • Vasily Nikolaevich Slautin Urals State Medical University, 3 Repin str., Ekaterinburg, 620028, Russian Federation https://orcid.org/0000-0002-5698-8404
  • Anastasia Dmitrievna Alexandrova Urals State Medical University, 3 Repin str., Ekaterinburg, 620028, Russian Federation https://orcid.org/0000-0002-3600-8894
Keywords: placental multipotent mesenchymal stromal cells, liver fibrosis, myofibroblasts, perisinusoidal liver cells

Abstract

A large number of chronic liver diseases, such as chronic viral hepatitis, alcohol intoxication, primary sclerosing cholangitis, autoimmune hepatitis and others, lead to the development of liver fibrosis. In the pathogenesis of the development of liver fibrosis against the background of the action of an etiological factor, the leading importance is assigned to the activation of perisinusoidal liver cells and their subsequent differentiation into myofibroblast-like cells, which are central regulators of fibrogenesis. In this study, allogeneic transplantation of multipotent mesenchymal stromal cells (MMSCs) isolated from the placenta in animals with liver fibrosis is performed. These cells are capable of synthesizing a number of factors that can potentially be considered antifibrogenic.

The purpose of the study was to evaluate the possibility of using placental multipotent mesenchymal stromal cells for the treatment of liver fibrosis.    

Methods. The experiments were performed on 40 male mice aged 8-10 weeks. Fibrosis was modeled by intraperitoneal injection of carbon tetrachloride in an amount of 2 µl/g of animal weight for 6 weeks, 2 times a week. Further, the animals in which liver fibrosis was induced were divided into the main group and the comparison group. The main group consisted of mice that received a single intravenous injection of MMSC in the amount of 1×10⁶ cells/ mouse in 0.2 ml. The comparison group consisted of mice that were not injected with cells after fibrosis modeling. 5 weeks after modeling liver fibrosis, the effectiveness of the therapy was evaluated. The culture of placental MMSCs was isolated from the chorion of the placenta according to the method of A.S. Teplyashin et al. 2004. The viability of the isolated cells was evaluated using 7-AAD. The METAVIR scale was used to assess the severity of fibrosis. Quantitative analysis of the collagen content in the liver was performed using the Picro Sirius Red Stain Kit. In the histological preparation of the liver, the number of MMP9, MMP13, TIMP1, α-SMA positive cells, CD45 positive cells was determined.  The content of growth factors HGF and TGF-β, Pro-Collagen I alpha 1 β, was evaluated in liver homogenate. Serum levels of proinflammatory cytokines were determined: interleukin-1β, tumor necrosis factor-α. The obtained data were processed by the variational statistical method using the Student's t-test. In the absence of a normal distribution, the statistical significance of the differences was determined using the nonparametric Mann-Whitney criterion (U). The differences were considered statistically significant at p<0.05.

Results. 5 weeks after modeling liver fibrosis on the background of MMSC transplantation, a decrease in fibrosis activity on the METAVIR scale by 50% was noted. MMSC transplantation was accompanied by a decrease in the content of CD 45+ cells in the liver. This led to a decrease in the level of proinflammatory cytokines in the blood serum. The introduction of MMSC was also accompanied by a decrease in the area of connective tissue by 33.1%. The area of the histological preparation stained with α-SMA, as well as the number of α-SMA positive cells after the introduction of MMSC decreased by 28.3% and 31.0%, respectively.  The introduction of MMSCs led to a decrease in the number of MMP9 and an increase in MMP13 producing cells, a decrease in the number of TIMP1 positive cells. A decrease in the level of TGF-β and an increase in HGF in the liver were also revealed. When analyzing the biochemical parameters of serum, it was found that the introduction of MMSC led to a decrease in the activity of transaminases, restoration of protein-synthetic liver function, and a decrease in the level of total bilirubin.

Conclusion. The results obtained indicate a high therapeutic potential of placental MMSCs. The use of MMSCs isolated from the chorion of the placenta can be considered as a promising non-surgical method for the treatment of liver fibrosis.

Downloads

Download data is not yet available.

References

1. Lee Ch., Kim M., Yoon M., et al. Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis. Biomedicines. 2021; 2;9(11):1598. doi: 10.3390/biomedicines9111598.
2. LV Y-F., Xie Ch-Sh., Liu Z-X., et al. Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells. Biochemical Pharmacology. 2024; 8:116121. doi: 10.1016/j.bcp.2024.116121.
3. Beeravolu N., McKee C., Alamri A., et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta. J. Vis. Exp. 2017; 3(122):55224 1–13. DOI: 10.3791/55224.
4. Stamatopoulos A., Stamatopoulos T., Gamie Z., et al. Mesenchymal stromal cells for bone sarcoma treatment: Road to clini8cal practice. J Bone Oncol. 2019; 19:16:100231. doi: 10.1016/j.jbo.2019.100231.
5. Peng Y-Q., Wu Z-C., Xu Z-B., et al. Mesenchymal stromal cells-derived small extracellular vesicles modulate DC function to suppres Th2 responses via IL-10 in patient with allergic rhinitis. Eur J Immunol. 2022; 52(7):1129-1140. doi: 10.1002/eji.202149497.
6. Li W., Jiang H., Feng J.-M. Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1, Mol Cell Biochem. 2012; 368(1-2): 137-45. doi: 10.1007/s11010-012-1352-5.
7. El-Derany M.O., Said R.S., El-Demerdash E. Bone Marrow-Derived Mesenchymal Stem Cells Reverse Radiotherapy-Induced Premature Ovarian Failure: Emphasis on Signal Integration of TGF-β, Wnt/β-Catenin and Hippo Pathways. Stem Cell Rev Rep. 2021; 17(4):1429-1445. doi: 10.1007/s12015-021-10135-9.
8. Moslem M., Valojerdi R.M., Pourmasr B., et al. Therapeutic potential of human induced pluripotent stem cell-derived mesenchymal stem cells in mice with lethal fulminant hepatic failure. Cell Transplant. 2013; 22(10):1785-99. doi: 10.3727/096368912X662462.
9. Xu Z., He B., Jiang Y., et al. Igf2bp2 knockdown improves CCl4-induced liver fibrosis and TGF-β-activated mouse hepatic stellate cells by regulating Tgfbr1. Int Immunopharmacol. 2022; 110:108987. doi: 10.1016/j.intimp.2022.108987.
10. Maruyama M., Rhee C., Utsunomiya T., et al. Modulation of the Inflammatory Response and Bone Healing. Front Endocrinol (Lausanne). 2020; 11;11:386. doi: 10.3389/fendo.2020.00386.
11. Maklakova I.Yu., Yastrebov A.P., Grebnev D.Yu. Changes in morphometric and cytological parameters of the spleen in acute blood loss against the background of stem cell administration. Uspekhi gerontologii.2015; 28(2): 218-221.(in Russian).
12. Arai Y., Lee S.-H. MMP12-Overexpressing Mesenchymal Stem Cella EnHance Bone Tissue Formation in the Presence of Collagen Hydrogel. Tissue End Regen Med. 2023; 20(3):461-471. doi: 10.1007/s13770-023-00535-y.
13. Hakki S. Bozkurt B.S., Hakki E.E., et al. SDF-1 modulates periodontal ligament-Mesenchymal Stem Cells (pdl-MSCs). J Periodontal Res. 2021; 56(4):774-781. doi: 10.1111/jre.12876.
14. Grebnev D.Yu., Maklakova I.Yu., Yastrebov A.P. The prospect of using stem cells to activate hematopoiesis in conditions of age-related involution against the background of the exposure to ionizing radiation. Uspekhi gerontologii.2014; 27(2):348-352.(in Russian).
15. Zhang X., Sharma P., Maschmeyer P., et al. GARP on hepatic stellate cells is essential for the development of liver fibrosis. Hepatol. 2023; 79(5):1214-1225. doi: 10.1016/j.jhep.2023.05.043.
16. Dhar D., Baglieri J., Kisseleva T., et al. Mechanisms of liver fibrosis and its role in liver сancer. Exp Biol Med. 2020; 245(2):96-108. https://doi.org/10.1177/153537021989
17. Roehien N., Crouchet E., Baumert T.F. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020; 3:9(4):875. doi: 10.3390/cells9040875.
18. Krenkel O., Puengel T., Govaere O., et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018; 67(4):1270-1283. doi: 10.1002/hep.29544.
Published
27-10-2025
How to Cite
Grebnev D. Y., Maklakova I. Y., Slautin V. N., Alexandrova A. D. Antifibrotic effect of placental multipotent mesenchymal stromal cells in liver fibrosis // Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2025. VOL. 69. № 4. PP. 89–100.
Section
Original research